AstraZeneca’s (AZN) Buy Rating Reiterated at Shore Capital

Shore Capital reaffirmed their buy rating on shares of AstraZeneca (LON:AZN) in a research report report published on Monday morning, Marketbeat Ratings reports.

Several other brokerages have also commented on AZN. Deutsche Bank Aktiengesellschaft restated a sell rating on shares of AstraZeneca in a research note on Tuesday, March 12th. Barclays reiterated an overweight rating and issued a £125 ($155.61) target price on shares of AstraZeneca in a research note on Monday, April 8th. Jefferies Financial Group reiterated a hold rating and issued a £110 ($136.94) target price on shares of AstraZeneca in a research note on Friday, February 16th. BMO Capital Markets reiterated an outperform rating on shares of AstraZeneca in a research note on Monday, February 12th. Finally, Berenberg Bank reiterated a buy rating on shares of AstraZeneca in a research note on Wednesday, March 13th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of Moderate Buy and an average price target of £115.43 ($143.69).

AstraZeneca Stock Down 0.1 %

LON:AZN opened at £108.62 ($135.22) on Monday. AstraZeneca has a twelve month low of GBX 9,461 ($117.78) and a twelve month high of £123.92 ($154.26). The company has a market cap of £168.36 billion, a price-to-earnings ratio of 3,584.82, a price-to-earnings-growth ratio of 0.89 and a beta of 0.19. The stock has a fifty day simple moving average of £103.49 and a 200-day simple moving average of £104.25. The company has a current ratio of 0.82, a quick ratio of 0.59 and a debt-to-equity ratio of 75.70.

AstraZeneca Increases Dividend

The company also recently announced a dividend, which was paid on Monday, March 25th. Investors of record on Thursday, February 22nd were issued a dividend of GBX 156 ($1.94) per share. This is an increase from AstraZeneca’s previous dividend of $71.80. The ex-dividend date of this dividend was Thursday, February 22nd. This represents a dividend yield of 1.49%. AstraZeneca’s payout ratio is 7,524.75%.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.